EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ceftazidime-avibactam resistance evolution in Pseudomonas aeruginosa and implications for cross-resistance to other novel β-lactams

Ava J Dorazio iD, Ellen G Kline iD, Kevin M Squires, Sunish Shah, Daria Van Tyne iD, Janet Y Wu, Jason M Pogue iD, Ryan K Shields iD

Antimicrobial Agents and Chemotherapy · 06.05.2026 · 70 (5)

DOI: 10.1128/aac.01910-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 06.05.2026. Verfasst von Ava J Dorazio und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Azabicyclo Compounds, Pseudomonas aeruginosa, Ceftazidime, Anti-Bacterial Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Twelve pairs of baseline and post-exposure Pseudomonas aeruginosa isolates from patients treated with ceftazidime-avibactam were evaluated to define mechanisms of treatment-emergent resistance. Resistance was associated with amino acid substitutions in ampC and OXA β-lactamases, or mutations in regulatory genes conferring hyper-production of AmpC and MexAB-OprM efflux pumps. Cross-resistance was common between ceftazidime-avibactam and ceftolozane-tazobactam, less common for imipenem-relebactam and cefepime-zidebactam, and lowest for cefiderocol. These findings have important implications for sequential treatment of P. aeruginosa infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Azabicyclo CompoundsPseudomonas aeruginosaCeftazidimeAnti-Bacterial Agentsbeta-LactamsMicrobial Sensitivity TestsCephalosporinsCefiderocolDrug CombinationsCefepimebeta-LactamasesBacterial ProteinsHumansTazobactamMembrane Transport ProteinsPseudomonas InfectionsImipenemBacterial Outer Membrane ProteinsDrug Resistance, Multiple, BacterialPenicillanic AcidAmino Acid SubstitutionMutationPiperidinesCyclooctanes

Stichwörter der Autor:innen

AmpCMexAB-OprM efflux systemcefepime-zidebactamceftazidime-avibactamceftolozane-tazobactamβ-lactam cross-resistance

Substanzen

Azabicyclo CompoundsCeftazidimeavibactam, ceftazidime drug combinationAnti-Bacterial AgentsCephalosporinsCefiderocolDrug CombinationsCefepimebeta-LactamasesBacterial Proteins

Autor:innen und Institutionen

  • Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Center for Innovative Antimicrobial Therapy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Center for Evolutionary Biology and Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA.
  • College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.

ORCID-Profile: Ava J Dorazio, Ellen G Kline, Daria Van Tyne, Jason M Pogue, Ryan K Shields

Zitieren

APA

Dorazio, A. J., Kline, E. G., Squires, K. M., Shah, S., Van Tyne, D., Wu, J. Y., Pogue, J. M., & Shields, R. K. (2026). Ceftazidime-avibactam resistance evolution in Pseudomonas aeruginosa and implications for cross-resistance to other novel β-lactams. Antimicrobial Agents and Chemotherapy, 70(5). https://doi.org/10.1128/aac.01910-25

Vancouver

Dorazio AJ, Kline EG, Squires KM, Shah S, Van Tyne D, Wu JY, et al. Ceftazidime-avibactam resistance evolution in Pseudomonas aeruginosa and implications for cross-resistance to other novel β-lactams. Antimicrobial Agents and Chemotherapy. 2026;70(5). doi:10.1128/aac.01910-25

BibTeX
@article{Dorazio2026,
  author = {Dorazio, Ava J and Kline, Ellen G and Squires, Kevin M and Shah, Sunish and Van Tyne, Daria and Wu, Janet Y and Pogue, Jason M and Shields, Ryan K},
  title = {Ceftazidime-avibactam resistance evolution in Pseudomonas aeruginosa and implications for cross-resistance to other novel β-lactams},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {5},
  doi = {10.1128/aac.01910-25}
}
Kostenlos starten →